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Abstract
Modern computational approaches tied together with the power of mathematical
science has pushed us closer to reach a deeper understanding of complex dynamical
systems. Real-world biological and physiological systems now can be studied on ac-
count of the accessibility to fast, cheap and powerful computers. In particular, the
field of neuroscience and brain data analysis has grown significantly in the recent
years. Recurrence plots (RPs) are a relatively new approach for the analysis of non-
linear, non-stationary and noisy data. Rooted in topological properties of the system,
RP visualizes the recurrence states of the dynamical system. Armed with the recur-
rence quantification measures, RP is even more rigorous in exploring and quantifying
real-world dynamical system.
In the present work, we benefit from the RP and RQA methods to study the be-
havior of intracranial pressure (ICP) waveforms. ICP is defined as the fluid pressure
inside the skull which carries important information associated with the status of
the patient. Our main goal is to detect sudden changes or extreme regime changing
in these signals. Patterns appearing in RP can shed light on fundamental charac-
teristics of the system. Our results suggest distinguishable patterns in the RPs of
some subjects which are not detectable in the raw ICP signals. This work sets up
the workflow for using RP analysis in online ICP monitoring of brain-injured patients.
Keywords: intracranial pressure (ICP) analysis, recurrence plot (RP), recurrence
quantification analysis (RQA)
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Chapter 1
Introduction and Background
1.1 Primary and secondary brain injury
Brain injuries are a major cause of death in the adult population under 45 years of
age worldwide (Jennett, 1996). Roughly speaking, 1.5 million individuals suffer from
Traumatic Brain Injury (TBI) in the United States annually. In Canada, uninten-
tional events including head-injuries were ranked in the top five causes of death from
2009 to 20131.
According to Brain Injury Canada, annually 160,000 Canadians are affected by
brain injuries. Statistics show that TBI is more common in males, particularly young
men (Stein, 2001), and often occurs as a result of impacts to the head in road ac-
cidents, falls and assaults. The reality that so many disabilities and even deaths
result from such events involving young people is troubling given that TBI imposes
many social and financial costs on society, estimated near $200 million (based on 1991
dollars) annually in the United States (Runge, 1993).
TBI outcome most often is directly correlated with the severity of the primary
injury; nonetheless, secondary brain injury also plays an important role. Primary
injury is defined as the direct damage of the physical impact to the intracranial
contents and occurs at the time of the incident, while secondary brain injury is defined
1Statistics Canada. Table 102-0561-Leading causes of death, total population, by age group and
sex, Canada, annual, CANSIM (database).
1
2as the damage and pathological conditions that develop over time as a result of
primary injuries and could occur shortly after the primary injury or many days after
admission to the intensive care unit (ICU) (Mendelow et al., 2005).
Secondary brain injury is caused by cerebral ischemia, cerebral hypoxia, inflam-
mation, seizure, etc. Cerebral or brain ischemia occurs when there is not enough
blood flow to the brain to fulfill the metabolic need for oxygen. Subsequently, this
lack of oxygen leads to damage and death of brain tissues. The damage could be to
a specific region of the brain (focal ischemia), or to larger areas (global ischemia).
Cerebral hypoxia occurs when the oxygen flow to the brain decreases. The causes
could be a reduction in blood flow (brain ischemia) or a problem in breathing or
blood oxygenation, etc. Brain herniation occurs when the intracranial pressure (ICP;
will be explained in the next subsection) increases above the normal value. Sustained
elevated ICP can cause serious damage to the brain which may result in moderate to
severe disability or even death. ICP elevation occurs when intracranial contents are
compressed and relocated due to the pressures caused by brain swelling, usually by a
brain tumor, head injury or stroke.
Unlike primary brain damage, some types of secondary brain injury can be pre-
ventable. Actively monitoring the patients can lead to an early and accurate diagnosis
of secondary brain injury which is a key factor in treatment and subsequently prevent-
ing further damage to the brain. ICP is one of the commonly monitored physiological
measures in criticality brain-injured patients. Although there is abundant research
that supports ICP monitoring and recommends it as one of the important indica-
tors in management guidelines for TBI, still some studies reject any difference in the
outcome of patients with ICP monitoring (Cremer et al., 2005; Dang et al., 2015).
31.2 Intracranial pressure
Intracranial pressure (ICP) is simply the fluid pressure inside the cranium. According
to the Monro-Kellie doctrine (Neff and Subramaniam, 1996), the skull is similar to
a closed box, containing a fixed volume of incompressible intracranial components.
ICP is defined as the pressures of these intracranial components: brain matter, cere-
brospinal fluid (CSF), and cerebral blood. The ICP value depends on age, body
position, and health condition and is altered by sneezing, coughing, Valsalva maneu-
ver, etc. In a healthy adult, ICP is normally between 7-15 mmHg in a supine position
(Brain et al., 2007). In young children and infants, ICP is lower at 3-7 mmHg and
1.5-6 mmHg, respectively (Greenberg and Arredondo, 2006). Although the ICP may
drop below the normal value, above-normal ICP is a more common and threatening
condition.
1.2.1 ICP hypertension
ICP could be increased in pathological conditions caused by disease or impact to the
head, for instance when an abnormal object, such as a tumor or a hematoma, is added
to the incompressible matter within the skull. Following the initial ICP increase, the
auto-regulation system controls and balances this increase by decreasing the cerebral
blood and fluid inside the skull. However, the auto-regulation mechanism is able to
keep the pressure equilibrium for only a short period of time, after which the ICP
elevation could cause damage to the brain tissue. Sustaining ICP values over 20 to
25 mmHg for more than at least five minutes is considered ICP hypertension and can
cause severe brain damage if untreated.
Following severe TBI, it is very likely that patients develop ICP hypertension and
the correlation between intracranial hypertension and TBI outcome is well established
(Juul et al., 2000; Kim, 2011; Mayer and Chong, 2002). It has been shown that in-
4creased ICP is associated with poor outcomes in TBI (Miller et al., 1977; OP´helan
et al., 2009) and has a mortality rate of 20% (Fakhry et al., 2004).
According to a study by OP´helan et al. (2009), ICP hypertension occurs in four dis-
tinguishable patterns in TBI patients: early, late, bimodal and continuous. Early/late
ICP hypertension is defined as when the pressure increases within/after 72 hours of
TBI. Bimodal ICP involves two separate increases, first in the early stage and then
again in the late stage, while in the continuous pattern the ICP increases continu-
ously and does not abate once it has begun. Although it is a common belief that most
secondary brain injuries develop in the first 72 hours after primary injury, Johnston
et al. (1970) suggest that ICP monitoring should be continued after the first 72 hours
even in patients for whom ICP is normal during this period of time. The authors
found that 17% of the patients in their dataset developed an increased ICP described
by the late pattern, with a peak time of 7 days post-injury.
1.2.2 ICP monitoring
ICP monitoring is one of the brain-specific monitoring criteria in the neurocritical care
unit. ICP monitoring usually is applied on comatose patients, patients suspected
of primary and secondary brain injuries, patients suffering from stroke or tumor,
and patients with neurological problems which have remained undiagnosed by other
medical examinations. Two types of ICP monitoring exist: invasive and noninvasive
operations.
External ventricular drain (EVD) is the most common invasive ICP measurement.
EVD is a moderately invasive ICP procedure in which a medical professional inserts a
catheter into the lateral ventricular region of the patient’s skull. The pressure is then
recorded at a specific frequency and the bedside monitor displays the values. The
monitoring time varies depending on ICU medical staff choices, however, a minimum
of 30 seconds is needed for a standard ICP recording. EVD may include some risks,
5such as bleeding, infection, brain tissue damage and brain herniation.
Some examples of noninvasive techniques includes Transcranial Doppler Ultra-
sonography (TCD), Tympanic Membrane Displacement (TMD), and Optic Nerve
Sheath Diameter (ONSD). In general, these methods attempt to estimate the ICP
value from noninvasive measures that are correlated with the ICP. However, up to
this date, the accuracy of noninvasive techniques tend to have high inter-subject vari-
ability and are not adequate enough to replace invasive procedures (Raboel et al.,
2012).
1.2.3 ICP waveform
The ICP waveform is composed of three components: the pulse waveform, the res-
piratory waveform, and the slow waveform. These components overlap in the time
domain, but are separated in the frequency domain (Czosnyka and Pickard, 2004).
In the time domain and on a scale of milliseconds, the ICP waveform displays three
upstrokes in one wave. These are P1, the percussion wave, which represents atrial
pulsation; P2, the tidal wave, which represents intracranial compliance; and P3, the
dicrotic wave, which represents aortic valve closure.
ICP waveforms can display four clinical statuses: normal, A, B, or C waves. In
a normal ICP waveform, P1 and P3 should have the highest and lowest upstrokes
respectively, and P2 should be in the middle. If P2 is higher than P1, the patient
suffers from intracranial hypertension (Kirkness et al., 2000).
The A wave (or plateau wave) is the most alarming type of ICP waveform and
represents secondary brain injuries such as ischemia. This wave is recognized with
an abrupt elevation in ICP to 50-80 mmHg that persists for more than five minutes.
In B and C waves, elevations of ICP also occur, where in the former the increase is
semi-periodic to 20-30 mmHg, while in the latter the increase is to a maximum of 20
mmHg with a frequency of 4-8 per minute (Lundberg et al., 1965).
6Figure 1.1: Simplified ICP waveform in a healthy person. Percussion, tidal, and
dicrotic waves are tagged with P1, P2, and P3, respectively.
Although the ICP mean value is important and helpful in clinical diagnoses, ex-
ploring the ICP waveform could reveal much more information about the dynamics
of this system that are useful for prognostic and diagnostic applications. Like other
complex biological systems, the ICP waveform represents a low-dimensional projec-
tion of a complex, high-dimensional system of its underlying components and their
interactions. Any small change in these components will affect the whole system.
1.3 Previous work on ICP analysis
As mentioned in the previous section, researchers have made many efforts to study
and explore ICP signals (Di Ieva et al., 2013). However, compared to other brain data,
such as EEG, ICP research still has a long way to go, particularly in signal processing.
Although today most physicians and researchers appreciate the importance of ICP
monitoring, there are concerns that the only information currently used in clinical
decisions is the mean ICP value, ignoring other types of potentially important infor-
mation the signal carries regarding cerebrospinal pathophysiology (Czosnyka et al.,
72007). The majority of studies utilizing machine learning and data mining techniques
have attempted to provide a proactive manner for treatment of brain-injured patients
by forecasting intracranial hypertension (ICH) and intracerebral hemorrhage from
the ICP waveform. Moreover, some studies have focused on the correlation between
the complexity of ICP signals and patient outcomes. Here, we provide a review of
some of the most important previous work on ICP analysis.
1.3.1 ICP hypertension forecasting
It has been more than 30 years since scientists first tried to develop a framework for
predicting ICP hypertension (IH), and a number of predictive features of the ICP
time series have been suggested in the literature.
A fairly recent work on ICP analysis is an algorithm titled Morphological Cluster-
ing and Analysis of Intracranial Pressure (MOCAIP), proposed by Hu et al. (2009).
The MOCAIP pipeline applies various data analysis methods (described below), sig-
nal processing and optimization techniques. The authors propose and validate this
algorithm for analyzing continuous ICP waveforms. The inputs of this algorithm are
the ICP and ECG signals and the outputs are the noise-filtered ICP signals with the
sub-peaks identified. The authors claim that the algorithm improves the quality of
the ICP signals by filtering noise as well as optimally determining the three sub-peaks
in an ICP pulse.
Briefly, the algorithm consists of five main stages: pulse detection, pulse cluster-
ing, legitimate pulse recognition, peak detection and peak designation. In the pulse
detection step, ECG beats are found using a method known as ECG QRS detection
(Afonso et al., 1999). At this stage, the authors use an algorithm presented in their
previous work (Hu et al., 2008) to construct the ICP pulse. The pulse clustering step
filters out noise and artifacts to achieve filtered representative pulses instead of raw
pulses. First, the pulses are clustered using Euclidian distance. Then the dominant
8pulse is defined as the average of the largest cluster and will be used for future anal-
yses. However, it is possible that the dominant pulse can be completely noise (for
example when the probe is detached) and should be removed from further analyses
in the legitimate pulse recognition phase. In the peak detection and peak designation
phases, three sub-peaks are detected for each legitimate dominant pulse using 24 MO-
CAIP metrics. Lastly, the algorithm is validated by comparing its results with the
expert observations of a healthcare professional. Another study used experimental
assessment to evaluate this methodological framework. The authors observed high
specificity and low sensitivity of detecting IH for this framework (Hu et al., 2010).
In another study, the authors apply the MOCAIP algorithm, as well as a quadratic
classifier (QDC), to forecast intracranial hypertension, which they define as any ICP
time window during which pressure exceeds 20 mmHg for a minimum of 5 minutes.
The authors claim that the ICP signal prior to intracranial hypertension could be dif-
ferentiated from normal ICP signals. They provide a quantitative method by which to
differentiate benign ICP elevations from possibly dangerous plateau waves (Hamilton
et al., 2009).
Specifically, Hamilton et al. (2009) consider four different segments of the ICP
signal: the beginning of intracranial hypertension and 5, 20 and 25 minutes before
the IH starts. Then for each of these four segments, they determine a combination
of metrics with the most predictive power among the 24 metrics of the MOCAIP
algorithm. In this study, the authors used data from 37 patients hospitalized at
the UCLA Medical Center. Patients had conditions that required ICP monitoring,
such as hydrocephalus (accumulated cerebrospinal fluid in the skull) and shunt mal-
function problems. The authors proposed a method by which to forecast potentially
harmful ICP elevations in order to prevent erroneous diagnoses of plateau waves and
over-treatment. Their results offer a forecasting horizon of five minutes with 90%
sensitivity and 75% specificity.
9So far, we have reviewed the studies that have considered ICP signals in the time
domain where usually the focus is to detect the three sub-peaks in the waveform. It is
worth mentioning that besides the more commonly used time domain analysis, there
is another type of ICP analysis that focuses on the frequency domain of the signals.
However, Holm and Eide (2008) claim that the time domain analysis is a better
approach. The authors compared the frequency domain and time domain methods
and concluded that applying the former causes a significant information loss due to
heavy data compression.
1.3.2 ICP waveform complexity and entropy
It’s not a straightforward task to define complexity, however, it can be considered as
a characteristic of a dynamical system that makes it able to react to even extremely
small changes in that system. Several studies have explored the complexity of the
ICP waveform during the course of intracranial hypertension and the correlation of
this complexity with patient outcome. Hornero et al. (2005, 2006) used Approximate
Entropy to study the complexity of ICP signals during the course of acute ICP hy-
pertension (ICP spike). In general, entropy is a measure of the predictability and
randomness of a stochastic process. Approximate Entropy (ApEn), which was used
by the authors, is one of the common techniques for measuring the regularity of ex-
perimental data, particularly medical data such as heart rate. ApEn could be applied
to systems with little or no prior knowledge, allowing it to analyze relatively short
and noisy time series. ApEn is model independent and scale invariant and in other
applications this metric has been shown to reveal patterns that are indistinguishable
and hidden by other classic time series analyses.
Hornero et al. (2005, 2006) studied the ICP data of seven pediatric patients (ages
between 4.5 to 15.5) with severe TBI. They define normal ICP as less than 20-25
mmHg and IH as ICP of more than 25 mmHg for a minimum of 5 minutes. They found
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11 ICP spikes in these seven subjects using a spike detection algorithm. The authors
evaluated the approximate entropy during the period of ICP spikes and observed that
the complexity of ICP decreases in IH periods. They also estimated the approximate
entropy for various synthetic signals with different properties, such as sinusoid pulse
noise, noise power and noise bandwidth, in order to gain a better insight into ApEn
itself.
The decrease in ICP complexity has also been demonstrated in another study
wherein the authors measured the complexity with Lempel-Ziv (LZ) complexity (Hornero
et al., 2007). The LZ algorithm is mostly popular for its data compression applica-
tions. Beside, LZ is also associated with Kolmogorov complexity (Kolmogorov, 1965)
and used as a measure of complexity and randomness for discrete-time biological sig-
nals. The LZ algorithm represents the rate of new patterns that occur in the system
over time; hence, a higher value of LZ complexity means a more complex system.
In spite of the popularity of LZ complexity metric, there are some criticisms of
applying the classic LZ to physiological data. In the classic LZ algorithm (CLZ) the
original time series is transformed into a binary sequence, using a threshold which is
often the median or mean of the series. This transformation may result in the loss
of useful information or altering the dynamical properties of the data (Zhang et al.,
2016). Various extensions have been proposed in order to improve the CLZ algorithm.
For instance, the multistate LZ complexity algorithm proposed by Sarlabous et al.
(2009). Hu et al. (2006) also investigated the effect of the data size on LZ complexity
and proposed a new normalization scheme that is almost independent of the length
of the data sequence.
Hornero et al. (2007) proposed preliminary results for the possibility of IH detec-
tion from non-invasive signals such as pulse oximetry coupled with ICP. In another
study, the authors observe that the outcomes in patients with TBI correlate with ICP
waveform complexity (Lu et al., 2012). The authors applied multiscale entropy anal-
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ysis and showed that patients who display reduced complexity of mean ICP waveform
are more likely to have poor outcomes.
1.3.3 ICP waveform nonlinearity
Nonlinearity is one of the fundamental properties of almost all real-world systems,
and intracranial pressure is not excluded from this fact. A nonlinear or complex
system consists of different components that interact with each other in a nonlinear
manner. Any small change in a nonlinear system can lead to a dramatic change in the
whole system. In contrast to linear systems, nonlinear systems are far more difficult
to predict and so cannot be easily understood. Nonlinear systems are almost always
irreducible, which means in order to study their behavior, the whole system must be
considered at once and it is typically uninformative to study any nonlinear system by
examining its parts individually (Goldberger, 1996).
Traditional techniques often fail when applied to nonlinear and complex systems.
Therefore, researchers have applied modern statistical physics and mathematics in
order to study these systems. One example of these studies is work by Stanley et al.
(1999) in which notable physiologic structures in heart rate dynamics were discovered
that were undetectable with traditional methods. The authors found that the non-
equilibrium behavior of the healthy heart is altered by pathological conditions such
as congestive heart failure.
The dynamic of the ICP waveform is also nonlinear and complex, and these char-
acteristics require further study using nonlinear approaches and considering all un-
derlying parameters. One of the nonlinear techniques that researchers have applied
to ICP waveforms is fractal analysis (Burr et al., 2008; Fan et al., 2010; Sourina et al.,
2010). Fractal analysis determines the self-similarity properties of irregular and com-
plex systems. In other words, the property of self-similarity means that the object
(spatial or temporal) displays the same shape/pattern at different scales. Fractal di-
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mension (FD) is the measure that describes fractal analysis quantitatively. Different
methods compute the FD; however, in biomedical studies, the box-counting method
is the most commonly used.
Sourina et al. (2010) applied fractal analysis to the ICP waveforms of 9 patients
before and after decompressive craniectomy surgery in order to detect the transition
phases in each patient’s status. The authors concluded that the fractal dimension
value is a reasonable indicator for determining whether surgery is required.
1.4 Recurrence plots
Dynamical systems are ubiquitous in the natural world and consequently our daily
lives. Thus, understanding, analyzing and forecasting these systems are crucial
tasks in many fields of science. These real-world systems are mostly nonlinear, non-
stationary in time, noisy, and often comprise many coupled variables. In addition,
according to Chaos theory, some of these systems are very sensitive to the initial
conditions and a very small perturbation of initial conditions results in dramatic al-
terations in the system. Such systems defy complete and precise prediction due to
the complexity raised from these characteristics.
Supposing many of the real-world systems are rule-driven and deterministic, short-
term and approximate prediction for them via mathematical modeling and computa-
tional solutions has been the focus of research. With the emergence of cheap powerful
computers many of these systems can be numerically approximated with arbitrary
resolution. However, predictions are always limited to the short term due to uncer-
tainties in the initial conditions. In order to overcome this challenge, other methods
are needed to discover the invariant properties of a dynamical system which are in-
dependent of the initial conditions.
In contrast to linear approaches that are mostly well-established and acknowl-
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edged, nonlinear methods are still controversial. Common nonlinear methods, such
as calculating the Lyapunov exponent, different entropy methods such as Kolmogorov-
Sinai entropy, and correlation dimension, have been proposed for the study of systems
that are stationary in time. More recently, different methods have been introduced to
study non-stationary real-world dynamics. Recurrence plots and recurrence quantifi-
cation analysis, used in this work, are relatively new methods for studying nonlinear
systems with regard to the topology of the system. Recurrence plot theory is founded
on the Poincare´ recurrence theorem (Poincare´, 1890), and Takens’ embedding the-
orem (Takens et al., 1981). Therefore, in order to have a better understanding of
the RPs method, these two important theorems are introduced very briefly in the
following subsections.
1.4.1 Phase space and trajectories
Trajectories and their representations in phase space are fundamental concepts in the
study of nonlinear systems from the topological point of view. The phase space of a
dynamical system is defined as all the possible states that the system could be found
in. For one/two dimensional systems with one/two variable(s) the phase space is
respectively a line (phase line) or a 2-D plane (phase plane). Now, consider a system
with d variables. At time t, the system and its velocity are described by:
~x(t) = (x1(t), x2(t), ..., xd(t)), (1.1)
~˙x(t) =
dx(t)
dt
. (1.2)
The phase space of this system is a d-dimensional space wherein as time evolves the
vector ~x(t) moves in the direction of its velocity and forms the phase space trajectories.
In any time t, the velocity field ~˙x(t) is tangent to the vector x(t). Accordingly, knowing
~˙x(t) makes it possible to determine the phase space trajectories of ~x(t) without having
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the exact expression of it or being necessary to find ~x(t) via integration.
Phase space trajectories reveal significant information regarding the behavior of
underlying system. Recurrence plots were initially proposed in order to study the
phase space trajectories of a high dimensional system, with the goal of providing a two-
dimensional visualization tool for such systems and gaining a deeper understanding
of their temporal dynamics (Marwan, 2008).
1.4.2 Poincare´ recurrence theorem
The Poincare´ recurrence theorem (Poincare´, 1890) is often the first concept that is
explained in ergodic theory. Roughly speaking, this theorem states that a measure-
preserving system2 will recur to a state close to its initial state, after a sufficiently
long but finite time. The proof of this theorem is beyond the scope of this thesis.
1.4.3 Takens’ embedding theorem
Phase space reconstruction plays a critical role in exploring the real-world time series.
In such systems, is not possible to determine all involved variables, as they are not
always known or measurable. Instead, often only one observation of the process is
available which is a discrete time series. Takens’ theorem (Takens et al., 1981) opened
a new chapter in the study of nonlinear systems by providing the essential theoretical
bases for analyzing real-world and experimental time series.
Takens et al. (1981) proved that phase space reconstruction is still possible having
only a single observation of a dynamical system; in a way that the new system does
preserve the topological structure and properties of the original system. Takens’
theorem was indeed a specific case of the Whitney embedding theorem (Whitney,
1936) and proved that a phase space can be reconstructed with the time-delayed
2(X,T, µ) is a measure-preserving system if (X,µ) is a measure space and T : X → X preserves
µ.
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versions of a single time series.
Roughly speaking, Takens’ theorem states that a phase space of a dynamical
system can be reconstructed3 (under certain conditions) in a way that the topological
properties of the original system are preserved.
Time delay embedding is one of the common methods for phase space recon-
struction. Assume the observation time series with sampling time of ∆t is vector
ui = u(i∆t), where i = 1, ... ,N . Then with the time delay embedding technique:
~xi =
m∑
j=1
ui+(j−1)τej (1.3)
where τ is the time delay and m is the embedding dimension (Marwan et al., 2007).
1.4.4 Recurrence plots definition
Recurrence is a fundamental concept in dynamical systems and is defined as the
recurrence of the system to the (almost) same state after finite time. The original
intuition of recurrence was introduced in the 19th century, however, it was not until
1987 that Eckmann proposed the recurrence plot (Eckmann et al., 1987). In addition
to recurrence plots, other techniques such as first return maps, space time separation
plots, and recurrence time statistics, are all based on the recurrence concept.
Recurrence plots are powerful visualization tools to display the recurrence states
of a dynamical system in a temporal manner. Moreover, these plots are able to
shed light on other characteristics of the system due to their associations with many
fundamental properties of the system, such as Pesins dimension, Lyapunov exponents,
Hausdorff dimension and various types of entropy. Armed with the powerful method
of recurrence plots, we are able to analyze short, noisy and non-stationary time series,
which are hard to study with other methods.
3This reconstruction is guaranteed when m > 2D+ 1, where m is the embedding dimension and
D is the correlation dimension of the attractor.
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Recurrence plots are based on a binary square matrix Ri,j, for i,j= 1, 2, ..., N :
Ri,j =

1, if xi ≈ xj
0, otherwise
Webber Jr and Marwan (2015) defined Ri,j as:
Rm,εii,j = Θ(εi − ‖xi − xj‖), xi ∈ Rm, i, j = 1...N (1.4)
Where N is the number of states or data points, εi is the threshold (will be explained
later), ‖.‖ is the norm, and Θ is the Heaviside function. Both axes of the recurrence
plot are time, and the recurrence points (Ri,i = 1) make the main diagonal line called
the line of identity (LOI). The threshold (εi) and norm are two important factors in
constructing insightful RPs for a dynamical system and choosing them properly is a
crucial task.
1.4.5 Embedding dimension
Eckman originally defined the RPs on a reconstructed phase space and an embedded
system, hence, the original definition of RP includes two embedding variables, the
embedding dimension and time delay. In general, finding the proper embedding
variables for a system is not a trivial task.
More recently, some studies have demonstrated that the RP can be constructed on
a non-embedded system and still display the same (or similar) results as the embedded
system (Iwanski and Bradley, 1998; March et al., 2005; Marwan et al., 2007). Thiel
et al. (2004) investigated this matter with an example where they demonstrated
that the correlation dimension and Re´nyi entropy statistics of a dynamical system
estimated from its RPs stay invariant with the change of the embedding dimension.
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1.4.6 Norm and threshold
Defining appropriate choices for threshold and norm is essential in constructing RPs
and depends mainly on the properties of the dynamical system under study (Marwan
et al., 2007). Different types of norms make different shapes of neighborhoods. The
L1-norm, the L2-norm, and the L∞-norm are three of the most commonly used norms
that respectively find the least, the most, and an intermediate number of neighbors for
a particular state. The L∞-norm is more efficient computationally and more common
as a result.
The choice of threshold is more influential on the RPs and needs to be chosen
carefully. Improper choices of threshold can result in spurious recurrences in the
case of a large threshold, or lead to the loss of real recurrence states in the case of
small threshold. Some rules for a proper choice of threshold have been proposed. For
example Mindlin and Gilmore (1992) suggested a few percent of the maximum of
phase space diameter for the threshold value, while Zbilut and Webber (1992) stated
that this value should be more than 10% of the maximum of phase space diameter.
1.4.7 Structures in recurrence plots
As mentioned before, RPs are visualization tools for displaying the recurrence states
of trajectories of a dynamical system in a temporal manner. RPs exhibit specific
patterns which shed light on important information about the trajectories and be-
havior of the system associated with the recurrence properties. The RPs’ patterns are
categorized in large and small scale patterns. The following are the typical patterns
that appear in RPs and their brief interpretation (Marwan et al., 2007).
Large-scale patterns
• Homogeneous RPs represent that the underlying dynamical system is a sta-
tionary system. e.g stationary random time series.
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• Diagonal lines in RPs represent periodic and quasi-periodic systems. The RPs
of such systems often display diagonal oriented checkerboard structures. The
frequencies of the system can be determined based of these patterns.
• Drift in RP represents a non-stationary systems with variables that are chang-
ing slowly. This slow change results in a pattern that is paling (or darkening)
away from the main diagonal.
• White areas or bands: in RPs represent sudden changes or extreme events
in systems.
Small-scale patterns
Besides large-scale patterns of RPs, small-scale patterns (also called texture) are
another means of extracting information from RPs. These patterns are also the
ground of the quantification analysis which will be introduced in the next section.
• Single recurrence points in RPs can happen in the case that a state is rare,
experiences extreme fluctuation or happens for a very short time.
• Diagonal lines which are parallel lines to the LOI, happen when two parts of
trajectories are (almost) parallel. Assuming k is the diagonal line length, for
k = {1, ..., l}, mathematically this corresponds to: Ri+k,j+k = 1.
• Vertical/horizontal lines in RPs occur when a state does not have alteration
for a period of time, or alters very slowly. Assuming k is the vertical line length,
for k = {1, ...,m}: Ri,j+k = 1.
Even supposing the mentioned patterns and their explanations have been intro-
duced and discussed in various articles, still a proper interpretation of these patterns
requires a decent background and can be somewhat subjective in some cases. This
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challenge can be overcome with the more objective approach to RPs, recurrence quan-
tification analysis, which we introduce in the following section.
1.4.8 Recurrence quantification analysis (RQA)
A few years following the introduction of RPs, Webber and Zbilut proposed several
quantification measures in order to standardize and facilitate the interpretation of
these graphical tools (Webber and Zbilut, 1994; Zbilut and Webber, 1992). These
measures made the RP method more rigorous since they enhanced it with well de-
fined quantitative descriptions. Recurrence quantification analysis (RQA) is applied
to estimate the complexity of the nonlinear system. These measures are related to
the RP’s recurrence density, diagonal and vertical lines. Here, we introduce the RQA
formulas with a brief explanation for each one (Marwan et al., 2007). It should be
mentioned that the LOI is usually excluded form RQA analyses. In the following, N
is defined as the number of data points which is the number of phase space points.
• Recurrence rate measures the density of the recurrence points in the system.
RR =
1
N2
N∑
i,j=1
Ri,j (1.5)
where Ri,j is the recurrence matrix. The average number of neighbors for each
point is also defined as:
Nn =
1
N
N∑
i,j=1
Ri,j (1.6)
• Determinism measures the percentage of the recurrence points of the diagonal
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lines.
DET =
N∑
l=lmin
lP (l)
N∑
l=1
lP (l)
(1.7)
where P (l) is the histogram of the lengths of the diagonal lines. Systems with
deterministic behavior display long diagonal lines, while chaotic systems often
includes short or no diagonal lines. A high DET value indicates a more pre-
dictable and less complex system.
• Average diagonal line length measures the average time that two segments
of the trajectory are in a same neighborhood.
L =
N∑
l=lmin
lP (l)
N∑
lmin
lP (l)
(1.8)
• Longest diagonal line length measures the maximum length of diagonal
lines.
Lmax = max ({li; i = 1, . . . , Nl}) (1.9)
where Nl is the number of diagonal lines in the recurrence plot and li is the
length of the diagonal line. Accordingly, Divergence is defined as:
DIV =
1
Lmax
(1.10)
A high DIV value indicates that the diagonal lines are short and the trajectory
segments diverge fast.
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• Entropy measures the Shannon entropy (and accordingly the complexity) of
the RP in regard to the diagonal lines.
ENTR = −
N∑
l=lmin
p(l) ln p(l) (1.11)
where p(l) is the probability of finding a diagonal line with the length of l in
the RP, p(l) = P (l)/Nl.
• Laminarity measures the percentage of the recurrence points of the vertical
lines.
LAM =
N∑
v=vmin
vP (v)
N∑
v=1
vP (v)
(1.12)
where P (v) is the histogram of the lengths of the vertical lines.
• Longest vertical line length measures the maximum length of vertical lines.
Vmax = max ({vi; i = 1, . . . , Nv}) (1.13)
where Nv is the number of vertical lines in the recurrence plot and vi is the
length of the vertical line.
• Trapping time measures the average of the vertical lines’ length.
TT =
N∑
v=vmin
vP (v)
N∑
v=vmin
P (v)
(1.14)
The TT value measures the mean time that a system is trapped in a particular
state.
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1.5 Thesis Statement and Contribution
Here we propose a novel approach for analysis of ICP waveform in brain-injured
patients. To our knowledge, this is the first study that applies recurrence plots and
recurrence quantification analysis to ICP data. The research question of this thesis is
to determine whether these methods have the potential of analyzing the ICP data for
identification of ICP hypertension. If so, they may be capable of revealing information
and should be further studied.
In the next chapter we present our results which are the RPs and RQA measures of
all 30 available subjects. We then discuss the results and findings. Our main finding
can be summarized as “the recurrence plots and recurrence quantification analysis
are capable of being used in ICP waveform analysis.”
Chapter 2
Methodology and Results
2.1 The MIMIC II data set
This study is based on version 3 of the MIMIC-II (multiparameter intelligent mon-
itoring in intensive care II) database (Saeed et al., 2011). MIMIC-II is one part of
an ongoing industrial and academic collaboration between MIT, Philips Healthcare,
and Beth Israel Deaconess Medical Center and is funded by the National Institutes
of Health (NIH). The goal is to provide open source ICU databases for researchers
and scientists by promoting patient monitoring and treatment in intensive care units.
MIMIC-II is freely accessible via the Physionet website.
The Physionet website provides physiological databases (PhysioBank), related
software and tools (PhysioToolkit) and related articles and publications (PhysioNet
Library) (Goldberger et al., 2000). PhysioBank offers over four terabytes of data,
organized into more than 80 databases including MIMIC-II. PhysioBank’s record
search is a powerful method through which users can find their desired datasets with
specific properties.
The MIMIC-II dataset contains clinical records from tens of thousands of neonate
and adult patients who have been hospitalized in different intensive care units of a
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single teaching hospital in the years 2001 to 2007. The data is anonymized completely,
which means all patient, family, and staff identifiers have been removed and all dates
have been changed for the sake of legal standards. The MIMIC-II is contained within
three databases: a clinical database (with restricted access), a waveform database
(with unrestricted access) and a matched database, which is a continuous effort to
match the waveform database with the corresponding clinical database.
The MIMIC-III database (Johnson et al., 2016) is a more recent project that has
been started to extend the MIMIC-II database and to update it by adding more recent
data from the years 2008 to 2012. On the MIMIC-III dataset, besides appending new
data, the previous raw data has been regenerated in order to achieve better quality,
accuracy and ease of use. The MIMIC-III is an ongoing project and its waveform
dataset was not available at the time of this study; therefore, we have used the
MIMIC-II database for our analyses.
2.1.1 Clinical database
The MIMIC-II clinical database was gathered from hospital archives and patient
bedside monitoring. This database consists of clinical records for 32,536 subjects
regarding the following information: general (patients’ admissions/discharges/death
dates, patient demographics, etc), physiological, medications, lab tests, fluid balances
(intake and output such as solutions/blood and urine/blood loss, respectively), notes
and reports. As mentioned previously, considering the sensitivity of this information,
all the data have been anonymized, the dates have been switched with fake dates
(although the time intervals have not been changed), and access to this database is
restricted to registered users of the Physionet website.
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2.1.2 Waveform database
The MIMIC-II waveform database contains physiological waveforms and numeric time
series of physiological measurements for approximately 13,500 ICU patients. The
lengths of the recorded signals and time series depend on the decisions that the ICU
medical staff have made for each patient. Mostly, the durations of the recordings
are a few days in length; nonetheless, shorter and longer lengths (hours or weeks,
respectively) also exist.
The waveforms were recorded at 125Hz and contain the following: electrocar-
diographic (ECG, measure of heart electrical activity), continuous blood pressure
(BP), plethysmogram (PLETH, measure of changes in blood volume) and respira-
tion (RESP). The ECG waveform itself includes: AVF, AVL, AVR, I, II, III, MCL,
MCL1, V1, and V2. The BP waveform includes: invasive arterial blood pressure from
two of the radial arteries (ABP and ART), cerebral perfusion pressure (CPP), central
venous pressure (CVP), femoral artery pressure (FAP), intracranial pressure (ICP),
left atrial pressure (LAP), pulmonary arterial pressure (PAP), right atrial pressure
(RAP), uterine arterial pressure (UAP) and uterine venous pressure (UVP).
Besides the mentioned signals, the MIMIC II waveform database also contains
records of numeric sampling over time. The sampling happens once per second or
once per minute; however, in the case of irregular sampling, the most recent value
has been recorded. These records contain temperature, heart rate (HR), cardiac
output (CO), carbon dioxide (CO2), respiration rate, oxygen saturation (SpO2), di-
astolic/systolic/mean blood pressure, etc.
2.1.3 Data preprocessing
For the data preparing process, the pipeline of an article by Hughes et al. (2017)
is followed and the same dataset is used. First, subjects with ICP recordings were
distinguished from others, and from those with ICP, subjects with a “consistent set”
26
of waveforms were selected. A total of 30 subjects were selected ( time series of these
subject IDs are included in the appendix.) with the following recordings: RESP,
PLETH, ECG-II, ECG-V, ECG-AVR, ABP, and ICP. In order to have a compre-
hensive analysis, and acknowledging all the underlying parameters, we consider all
available signals, in addition to the ICP. Here, each point is a length-seven vector of
values for different measurements at each timestamp. This assumes that the wave-
forms are aligned in time, which is a true assumption as all the signals have the same
frequency (125 samples per second) according to the data documentation.1
Although the signals are polluted with artifacts from different sources (explained
in the next subsection), we did not apply filters to the signals as suggested by Hughes
et al. (2017), in order to preserve them in a raw state. However, down-sampling by
a factor of five and z-score normalization were applied to the data. An example of
waveforms for one subject (3094054) is displayed in Figure 2.1. It should be mentioned
that in all figures the ICP is in mmHg and normalized.
2.1.4 Dataset limitations
Similar to other physiological data, ICP signal is noisy and polluted with high-
frequency and low-frequency artifacts. High-frequency noise is mainly caused by
the sensors or the process of converting analog signals to digital. Meanwhile, the low-
frequency noise is caused by coughing, sneezing or patient movements. According
to the MIMIC II documentation, another source of noise is the gap intervals which
occurred when the staff did not restart the monitoring machine for a new patient, or
when the recording probe was disconnected from the patient temporary.
Another constraint of the MIMIC-II dataset is that the signals are not labeled
with patients’ status. In other word, waveforms are not tagged with any information
regarding the onset and termination of patient’s critical events (e.g ICP hypertension
1The ECG signals were not sampled at the same frequency originally. However, these signals
have been reconstructed and are consistent with other signals.
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Figure 2.1: Time series of seven waveform recordings for subject 3094054: RESP,
PLETH, ECG-II, ECG-V, ECG-AVR, ABP, and ICP.
in the case of ICP waveform). Moreover, the clinical dataset contains important
and useful information of the patients such as the patient demographics, received
treatments and the patent’s outcome. However, only a few number of subjects possess
matched clinical and waveform datasets. The process of matching is in progress and
more matched records may be added in the future.
2.2 Recurrence plots
The recurrence plots for all 30 subjects has been generated. Moreoever, the global
recurrence plot which is the un-thresholded recurrence plot (or more simply the plot
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based on the distance matrix (Zbilut and Webber, 2006)) is also generated. The RPs
of some of the subjects are included in the next subsection, however, the complete
list of figures can be found in the Appendix. The RP parameters that are used in
these plots are as the following:
• N is the number of data points which is equal to 1400 in our study. It should
be mentioned that each data point in our dataset is a vector of length seven. At
time t, this vector contains the values of the following waveforms at that time:
RESP, PLETH, ECG-II, ECG-V, ECG-AVR, ABP, ICP readings.
• ε, the threshold, is set to 2. As suggested in the literatures (Schinkel et al.,
2008), we set the threshold as 10% of the maximal phase space diameter. This
value varies for different subjects with 1 ± .5 < ε < 2. We set the ε as the
upper bound which is 2. The reason of choosing the upper bound is that we
want to minimize the effect of noise on the potential patterns in RPs because
noise would alter these structures and a higher threshold may prevent noisy
alterations and preserve the larger patterns (Marwan et al., 2007).
• The norm considered is the L2-norm which is the Euclidean norm. Therefore,
the distance of two data points is the Euclidean distance of two vectors of
lengths seven.
• Lastly, although the original definition of RP, equation 1.4, is based on the
theory of the reconstruction of phase space and includes two embedding param-
eters; we do not apply embedding to our system. The reason, as mentioned in
Section 1.4.5, is that the non-embedded system can also display similar patterns
in its RP.
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2.2.1 Structures in RPs
The PR usually exhibit periodic patterns, whereas abrupt changes indicate a regime
change in the dynamics of the system. For example, Figure 2.2 illustrates the structure
observed in same subject as of Figure 2.1. The associated ICP and ECG-II waveforms
also are provided in the top of the RP in order to make the comparison of RP and
the raw signals possible.
As mentioned in the previous chapter, white regions or bands in the RP indicate
abrupt fluctuations in the system. Determining these sudden changes are really im-
portant in our study since they may be a sign of sudden change in the status of the
patient in, for instance, ICP hypertension.
In Figure 2.2 white bands are visible, the one at approximately time point t =
160 is more obvious which is a sign of visible change in that moment. This change is
also visible in the raw ICP signal.
Similar white bands are observable in RPs of eight subjects out of all the 30
subjects studied. While most RPs display periodic dynamics, these eight subjects
exhibit peculiar and surprising patterns in their RPs which are not always apparent
in their ICP signals. We specifically we plot the RPs for three more subjects here in
Figure 2.3, Figure 2.4, and Figure 2.5. The RP plots of all subjects are provided in
the appendix.
Figure 2.3, we see how subject 3094054 displays an extreme alteration in its RP. A
clear white band exists right before time point 200. The interesting point here is that
this event can not be detected form the raw ICP signal, which proves the significance
of RP.
In Figure 2.4, the RP shows two periods of rare states close to data points 400
and 1200. This may be an indication of regime change in these periods. These events
are visible in the raw ICP signal too.
Finally, we review one more subject in Figure 2.5 which exhibits a similar white
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Figure 2.2: Top to bottom, respectively: ECG and ICP signals and RP of patient
with ID 3094054. The data have the length 1400 (N = 1400). RP parameters are m
= 1,  = 2. At time point near t = 160 there is a white band which represents an
abrupt change in the signal data. This change can also be detected in the raw ICP
signal.
band in its RP plot, whereas we see a change in the periodic patterns before t = 1000;
this however is not detectable when looking at the raw timeseries.
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Figure 2.3: RP, ICP and EEG signals of patent with ID 3105502. The white band
close to time point 200 is a sign of extreme change in the system. This information
is not obvious in the raw ICP signal and emphasizes the utility of RP methods in
highlighting abnormalities and regime changes in such complex dynamic systems.
2.2.2 RQA
Although eyeballing the RP plots is possible, particularly in our case that the number
of subjects is not large, it is valuable to quantify the change in periodic patterns and
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Figure 2.4: RP, ICP and EEG signals of patent with ID 3779174. Two periods of rare
states around data points 400 and 1200 are displayed in the RP. Regime changing
events could be interpreted in these periods. Raw ICP signal also displays these
events.
surprisingness of observed dynamics. Therefore, we continue with the recurrence plot
analysis measures which are defined to quantify these changes given an RP matrix.
In more details, we calculate eleven RQA measures for each subject: RR: Re-
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Figure 2.5: RP, ICP and EEG signals of patent with ID 3646209. Here, we also see
a possible change as a white band, although less preeminent compared to the last
subjects.
currence Rate, DET : Determinism, L: Average diagonal line length, Lmax: Longest
diagonal line, DIV : Divergence of diagonal lines, ENTPL: entropy of diagonal lines,
LAM : Laminarity, TT : Trapping time, Vmax: maximum vertical line, and ENTPV :
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entropy of vertical lines. For their definition please refer to the previous Chapter. The
distribution of statistics of these RQA measures across all the subjects are calculated
and the results are given in Table 2.1, whereas Figure 2.6 shows the distribution in
boxplot format.
RQA median mean min max var cov
RR 0.164 0.169 0.135 0.352 0.001 0.001
DET 0.647 0.640 .518 0.812 0.007 0.007
C2 0.163 0.168 0.134 0.352 0.001 0.001
L 7.449 7.525 6.275 10.270 0.654 0.676
Lmax 184 237 58 1197 39570 40934
DIV 0.005 0.006 0.001 0.017 0.0 0.0
ENTPL 2,291 2.304 1.923 2.787 0.039 0.040
LAM 0.711 0.705 0.510 0.867 0.010 0.010
TT 4.551 4.693 3.386 7.776 0.788 0.815
Vmax 7.00 8.433 5.000 14.000 6.712 6.944
ENTPV 1.594 1.558 0.748 2.431 0.143 0.148
Table 2.1: Summary statistics of RQA measurements across subjects. The RQA
measures include: RR, DET, C2, L , Lmax, DIV, ENTPL, LAM, TT , Vmax.
V_entr LAM L_max RR TT DET L V_max L_entr C2 DIV
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Figure 2.6: Distributions of different RQA measures
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2.2.3 Anomalous Subjects
Using descriptive statistics of boxplot, shown in Figure 2.6, we can flag the subjects
that deviate from the distribution and mark them as anomalies. To find the outliers,
first the quartiles of the data are calculated and the interquartile range is computed
from the upper and lower quartiles, which is IQR = Q3−Q1. Then the whiskers are
plotted which extend to a point greater or lower than 1.5 ∗ IQR from the upper and
lower quartiles. Points outside of these are marked as outliers, which are those that
Q1 − x or x−Q3 is greater than 1.5 ∗ IQR.
The subjects with anomaly values have been identified and listed bellow:
• subject id 3096171 is a anomaly in ENRTV with value 0.747.
• subject id 3083337 is a anomaly in ENRTV with value 2.430.
• subject id 3505904 is a anomaly in Lmax with value 1197.
• subject id 3505904 is a anomaly in RR with value 0.352.
• subject id 3083337 is a anomaly in TT with value 7.776.
• subject id 3083337 is a anomaly in L with value 10.27.
• subject id 3505904 is a anomaly in C2 with value 0.352.
• subject id 3738640 is a anomaly in DIV with value 0.014.
• subject id 3623238 is a anomaly in DIV with value 0.011.
• subject id 3105502 is a anomaly in DIV with value 0.017.
Having these subjects flagged, we can now take a close look at their recurrence
plots to investigate the patterns and see if the abrupt changes are present. In partic-
ular, Figure 2.7 to Figure 2.12 show the (bounded and unbounded) PR plots of these
36
anomalies, along with the distribution of their diagonal and vertical lines which are
used to quantify the patterns in them in the RQA measures.
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Figure 2.7: Anomaly in ENRTV for subject id 3083337 has value 2.43
2.2.4 Novelty Curve of RP
We further investigate the novelty curve for the original time series, as well as the
distance matrix which is basis of the RPs. Figure 2.13 shows the novelty curve
derivation steps taken from an original time-series. From top to bottom, the ICP
waveform and four steps of amplitude squaring, windowing, differentiation, and half
wave rectification are shown respectively. In the first step the amplitude of the each
data point is squared. In the second step, each point is set to the mean of a window
of size 10 points. In the next plot, the differentiation of each point and its previous
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Figure 2.8: Anomaly in ENRTV for subject id 3096171 has value 0.75
point is computed. The last plot at the bottom shows the derived novelty curve after
half wave rectification which filters out the negative points.
Figure 2.14 shows the novelty curve of the distance matrix for the subject previ-
ously showed in 2.5. In order to build the novelty curve of a matrix, the differentiation
step is changed with Euclidean distance of subsequent columns. We can see the picks
in the novelty curve at around t = 200, t = 400, and t = 1000. This shows that the
picks at these novelty curves could also be used to detect changes in the PR plots.
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Figure 2.9: Anomaly in DIV for subject id 3105502 has value 0.018
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Figure 2.10: Anomaly in Lmax for subject id 3505904 has value 1197
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Figure 2.11: Anomaly in DIV for subject id 3623238 has value 0.011
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Figure 2.12: Anomaly in DIV for subject id 3738640 has value 0.014
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Figure 2.13: Novelty curve derivation from the original ICP time-series for subject
3029993
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Figure 2.14: Novelty curve of the RP matrix.
Chapter 3
Discussion and Conclusion
This thesis is an effort to address the intriguing question: In what ways do the
methods of recurrence plots and recurrence quantification analysis describe data form
nonlinear systems; and are they capable of revealing insightful information about the
dynamics complex dynamical systems and real-world time series? We investigate this
question in a more specific clinical context using intracranial pressure signals obtained
from human brain-injured patients; by narrowing it to one specific type of brain data:
intracranial pressure waveform.
Intracranial pressure is simply the pressure inside the skull. This pressure is the
result of incompressible components of the cranium: brain matter, cerebrospinal fluid
(CSF), and cerebral blood. It is shown in the literature that the waveform of this
pressure carries important information which can not be extracted with the scalar
ICP value which is most commonly used by medical professionals. Various methods
have been applied in order to explore and analyze these signals. We propose and use
the Recurrence Plot (RP) and Recurrence Quantification Analysis (RQA) to study
the dynamics of these waveforms.
The dataset used in this study only contains the physiological waveforms and not
the clinical information such as the reason of admission and the outcome of patents.
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Due to this constraint it is not easy to make interpretations of the RPs and the RQA
results nor to make forecasts and predictions. However, we show that these methods
clearly demonstrate the ability for analyzing these complex time series by visualizing
them into simple 2D plots and elucidating information in the signals that may not be
obvious in the signal itself, such as discontinuities in dynamics over time or descriptive
statistics on the properties of the system’s phase space.
We observe that the ICP waveforms can exhibit a rich variety of peculiar pat-
terns in their RP which are hidden in the raw signal. Further study on this regard
is needed to understand the relationship between these dynamic peculiarties and the
corresponding clinical outcome of the patients. Also, it should be stated that our
proposed analysis to spot changes might be too sensitive and further robustness ex-
periments could be a potential further work.
The presented work is only a small step in the tough task of understanding the
dynamics of ICP waveforms among a plethora of other clinical signals. This method
of ICP analysis could be merged with other works in this area or extended in many
different directions. One possible future direction is to use the recurrence approach
to understand the relationship between the ICP signals and other biological measure-
ments in order to develop non-invasive ICP monitoring framework with an acceptable
accuracy. The phase space reconstruction of these dynamic signals can give insights
into the relationships if biological signals. The second possible future work is to
use this methods in real-time ICP monitoring. Combining this approach with other
available methods and clinical data can allow medical experts to more easily under-
stand the long-term behavior of the ICP waveforms instead of only the mean, scalar,
ICP value. Another extensions to this work could be applying this method to a la-
beled ICP dataset in order to predict ICP hyperinflation. With appropriately labeled
data, it is possible to compare different parts of the ICP waveform (normal signal,
pre-hypertention and during hyperinflation) and train classifiers or apply machine
46
learning techniques to identify healthy patterns or those that can lead to secondary
injuries.
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Appendix A
Comprehensive Results
A.1 Overall Results
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Figure A.1: Distributions of RQAs for all subjects, anomalies are flagged, actual scale
of the figure provided in the main text.
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Figure A.2: Distributions of different RQA measures, from which the above box plot
is generated. The red curve is the Gaussian with same mean and variance, which
confirms these are not normal distributions.
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A.2 Novelty Curves of All Patients
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Figure A.3: Novelty curves of subject 3029993
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Figure A.4: Novelty curves of subject 3033031
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Figure A.5: Novelty curves of subject 3083337
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Figure A.6: Novelty curves of subject 3094054
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Figure A.7: Novelty curves of subject 3096171
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Figure A.8: Novelty curves of subject 3105502
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Figure A.9: Novelty curves of subject 3169632
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Figure A.10: Novelty curves of subject 3262086
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Figure A.11: Novelty curves of subject 3269261
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Figure A.12: Novelty curves of subject 3289177
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Figure A.13: Novelty curves of subject 3367596
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Figure A.14: Novelty curves of subject 3379471
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Figure A.15: Novelty curves of subject 3460047
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Figure A.16: Novelty curves of subject 3463681
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Figure A.17: Novelty curves of subject 3505904
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Figure A.18: Novelty curves of subject 3516004
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Figure A.19: Novelty curves of subject 3555523
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Figure A.20: Novelty curves of subject 3562822
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Figure A.21: Novelty curves of subject 3582988
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Figure A.22: Novelty curves of subject 3599360
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Figure A.23: Novelty curves of subject 3600995
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Figure A.24: Novelty curves of subject 3607634
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Figure A.25: Novelty curves of subject 3623238
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Figure A.26: Novelty curves of subject 3645431
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Figure A.27: Novelty curves of subject 3646209
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Figure A.28: Novelty curves of subject 3662063
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Figure A.29: Novelty curves of subject 3721988
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Figure A.30: Novelty curves of subject 3738640
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Figure A.31: Novelty curves of subject 3779174
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Figure A.32: Novelty curves of subject 3781713
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A.3 Distance and RP Matrices of All Patients
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Figure A.33: RQA results of subject 3029993
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Figure A.34: RQA results of subject 3033031
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Figure A.35: RQA results of subject 3083337
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Figure A.36: RQA results of subject 3094054
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Figure A.37: RQA results of subject 3096171
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Figure A.38: RQA results of subject 3105502
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Figure A.39: RQA results of subject 3169632
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Figure A.40: RQA results of subject 3262086
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Figure A.41: RQA results of subject 3269261
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Figure A.42: RQA results of subject 3289177
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Figure A.43: RQA results of subject 3367596
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Figure A.44: RQA results of subject 3379471
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Figure A.45: RQA results of subject 3460047
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Figure A.46: RQA results of subject 3463681
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Figure A.47: RQA results of subject 3505904
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Figure A.48: RQA results of subject 3516004
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Figure A.49: RQA results of subject 3555523
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Figure A.50: RQA results of subject 3562822
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Figure A.51: RQA results of subject 3582988
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Figure A.52: RQA results of subject 3599360
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Figure A.53: RQA results of subject 3600995
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Figure A.54: RQA results of subject 3607634
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Figure A.55: RQA results of subject 3623238
107
0 200 400 600 800 1000 1200 1400
Time
0
200
400
600
800
1000
1200
1400
Ti
m
e
Distance  of Patient #3645431
0
1
2
3
4
5
6
7
8
9
0 200 400 600 800 1000 1200 1400
Time
0
200
400
600
800
1000
1200
1400
Ti
m
e
RP  of Patient #3645431
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 50 100 150 2000
2000
4000
6000
8000
10000
12000histogram of diagonal lines  of Patient #3645431
0 50 100 150 200
100
101
102
103
104
105histogram of diagonal lines  of Patient #3645431
2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.00
5000
10000
15000
20000
25000
30000
35000histogram of vertical lines  of Patient #3645431
2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0
102
103
104
105histogram of vertical lines  of Patient #3645431
Figure A.56: RQA results of subject 3645431
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Figure A.57: RQA results of subject 3646209
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Figure A.58: RQA results of subject 3662063
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Figure A.59: RQA results of subject 3721988
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Figure A.60: RQA results of subject 3738640
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Figure A.61: RQA results of subject 3779174
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Figure A.62: RQA results of subject 3781713
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A.4 RPs and Novelty Curves of All Patients
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Figure A.63: RP and novelty curve of subject 3029993
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Figure A.64: RP and novelty curve of subject 3033031
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Figure A.65: RP and novelty curve of subject 3083337
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Figure A.66: RP and novelty curve of subject 3094054
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Figure A.67: RP and novelty curve of subject 3096171
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Figure A.68: RP and novelty curve of subject 3105502
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Figure A.69: RP and novelty curve of subject 3169632
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Figure A.70: RP and novelty curve of subject 3262086
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Figure A.71: RP and novelty curve of subject 3269261
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Figure A.72: RP and novelty curve of subject 3289177
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Figure A.73: RP and novelty curve of subject 3367596
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Figure A.74: RP and novelty curve of subject 3379471
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Figure A.75: RP and novelty curve of subject 3460047
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Figure A.76: RP and novelty curve of subject 3463681
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Figure A.77: RP and novelty curve of subject 3505904
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Figure A.78: RP and novelty curve of subject 3516004
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Figure A.79: RP and novelty curve of subject 3555523
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Figure A.80: RP and novelty curve of subject 3562822
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Figure A.81: RP and novelty curve of subject 3582988
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Figure A.82: RP and novelty curve of subject 3599360
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Figure A.83: RP and novelty curve of subject 3600995
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Figure A.84: RP and novelty curve of subject 3607634
137
0 100 200 300 400 500 600 700 8003
2
1
0
1
2
3
EC
G_
II
Timeseries with RP of Patient #3623238
0 100 200 300 400 500 600 700 8002
1
0
1
2
3
4
IC
P
0 100 200 300 400 500 600 700 8000
5
10
15
20
25
30
35
40
45
No
ve
lty
 C
ur
ve
 2
0 100 200 300 400 500 600 700 800
Time
100
200
300
400
500
600
700
800
Ti
m
e
Figure A.85: RP and novelty curve of subject 3623238
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Figure A.86: RP and novelty curve of subject 3645431
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Figure A.87: RP and novelty curve of subject 3646209
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Figure A.88: RP and novelty curve of subject 3662063
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Figure A.89: RP and novelty curve of subject 3721988
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Figure A.90: RP and novelty curve of subject 3738640
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Figure A.91: RP and novelty curve of subject 3779174
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Figure A.92: RP and novelty curve of subject 3781713
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